ArticleBioengineering & translational medicine2025
Micrometer-scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy.
Article in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Thrombolytic therapy in vertebrobasilar dolichoectasia patients with acute posterior circulation cerebral infarction: a case series analysis.Thrombosis journal · 2026Article
- Thermally assisted microbot transport through high-viscosity media.Scientific reports · 2025Article
- Micrometer-scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy.Bioengineering & translational medicine · 2025Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Rapid restoration of blood flow is critical in treating acute ischemic stroke. Current thrombolytic therapies using tissue plasminogen activator (tPA) are limited by low recanalization rates and risks of off-target bleeding. Here, we demonstrate that a remarkably simple adjustment-using micrometer-scale rather than sub-micrometer particles to immobilize tPA-fundamentally improves thrombolysis. By merely increasing the particle diameter from 0.1 to 1.0 μm, we achieve a dramatic shift in lysis dynamics: 1.0 μm tPA-beads generate higher plasmin flux, readily overcome antiplasmin inhibition, and trigger a self-propagating cascade of fibrinolysis. This leads to near-complete clot dissolution at tPA doses nearly 100-fold lower than standard free tPA, both in vitro and in a murine model of acute ischemic stroke. Within minutes, low-dose 1.0 μm tPA beads fully restore blood flow, outperforming conventional therapies. Our results show that simply scaling up particle size can resolve kinetic and transport barriers in thrombolysis, offering a promising advancement in stroke treatment with potential applications in other thrombotic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.